ClinicalTrials.gg
Active, not recruitingNCT07094516Updated Nov 5, 2026

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

A Phase 2 interventional study of VHB937 and VHB937 in Alzheimer's Disease, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 73 sites in 15 countries. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Updated Nov 5, 2026Now Active, not recruitingEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 36 studies in Alzheimer Disease by Novartis — none open to participants now, 2 under way, none of them phase 3. Alzheimer Disease · Novartis.

Enrollment
23rd of 35
96 · median 142
Started
2025
the only one that year
Phase 2
9 of 36
none open now
Registered
36th of 36
by date

Among the 36 studies in Alzheimer Disease by Novartis, this one is the 23rd largest by enrollment of the 35 interventional ones that give a count, is the only one that started in 2025, is one of 9 in phase 2, and was the 36th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

None of the 36 studies in Alzheimer Disease by Novartis is open now. The open studies under Alzheimer Disease, anywhere →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 36 studies in Alzheimer Disease by Novartis as a file.
02

Study summary

This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension. The double-blind part is 72 weeks long, followed by an extension.

Read the detailed description

The purpose of this study is to find out whether treatment with VHB937 is safe and beneficial in people with early Alzheimer's disease. The study will evaluate the safety of VHB937, as well as its effects on memory and other thinking abilities, on daily activities, and on changes in the brain. The study will also observe and measure how VHB937 is processed by the body and how the body responds to it.

03

Conditions studied

  • Alzheimer's Disease

Keywords

  • Alzheimer's disease
  • AD
  • Dementia
  • Monoclonal Antibody
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  • Male or female participants 50 to 85 years of age
  • Diagnosis of Mild Cognitive Impairment (MCI) due to AD or mild AD
  • Clinical Dementia Rating (CDR) Global score of 0.5 or 1.0
  • Confirmation of AD based on cerebral spinal fluid (CSF) biomarkers or amyloid PET imaging
  • Reliable study partner who can accompany the participant at study visits
  • If on symptomatic AD treatment (AChEIs/memantine), on a stable dose prior to starting study treatment

Key Exclusion Criteria

  • Dementia due to a condition other than AD, including but not limited to, frontal temporal dementia, Parkinson's disease, dementia with Lewy bodies, Huntington disease, vascular dementia.
  • History or current diagnosis of cardiac conditions or abnormalities indicating significant risk of safety for participants in the study
  • (TIA) or stroke occurring within 12 months
  • Clinical evidence of liver or renal disease/injury
  • Current major depressive episode that is not adequately controlled, history of schizophrenia, other chronic psychosis
  • Significant neurological disease other than dementia (e.g. serious brain infection, traumatic brain injury, multiple concussions, epilepsy or recurrent seizures
  • Presence of suicidal ideation within 6 months or suicidal behavior within 2 years before Screening
  • Presence of cancer, , Hep B, Hep C, uncontrolled thyroid disease, uncontrolled diabetes
  • Taking any prohibited medications

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    VHB937 Low Dose

    I.V. infusions

    Biological: VHB937

  • Experimental
    VHB937 High Dose

    I.V. infusions

    Biological: VHB937

  • Placebo comparator
    Placebo

    I.V. infusions

    Other: Placebo

Interventions

  • BiologicalVHB937

    VHB937 solution for infusion

  • BiologicalVHB937

    VHB937 solution for infusion

  • OtherPlacebo

    Solution for infusion

06

What researchers measure

Primary outcomes

  1. Change from Baseline in the Clinical Dementia Rating scale - Sum of Boxes (CDR-SB)

    The CDR is a measure of cognition and function, widely used in clinical research in AD. The scale assesses six domains: Memory, Orientation, Judgment \& Problem Solving, Community Affairs, Home \& Hobbies, and Personal Care. Based on in-depth semi-structured interview, each domain is assigned a score, which is summed to obtain the Sum of Boxes (SB) score, ranging from 0 to 18 with higher scores indicating worse condition

    Time frame: Baseline and Week 72

Secondary outcomes

  1. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Incidence and severity of AEs and SAEs by treatment group, including Safety findings, Laboratory tests, Vital signs and, ECG findings qualifying and reported as AEs.

    Time frame: From First treatment to end of study (up to 63 months approximately)

  2. Change from Baseline in Clinical Dementia Rating scale - Sum of Boxes (CDR-SB)

    The CDR is a measure of cognition and function, widely used in clinical research in AD. The scale assesses six domains: Memory, Orientation, Judgment \& Problem Solving, Community Affairs, Home \& Hobbies, and Personal Care.

    Time frame: Baseline over time until Week 72

  3. Change from Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog14)

    The ADAS-Cog is is a 14-item clinical assessment tool to measure cognition. The ADAS-Cog14 score ranges between 0 and 90, with higher scores indicating worse cognitive performance

    Time frame: Baseline over time until Week 72

  4. Change from Baseline in instrumental activities of daily living (iADL) on the Alzheimers Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) scale

    The ADCS-ADL is a 23-item study partner scale designed to assess the ability of patients with AD to carry out basic activities of daily living (bADLs) and instrumental activities of daily living (iADLs). For each item, the study partner is asked whether the participant attempted the activity in the 4 preceding weeks. Where 'yes' is the answer, the study partner is asked to rate the patient's level of performance according to a set of descriptors tailored to that activity. Scores on iADL sub-scale range between 0 and 59, with lower scores reflecting greater disease severity

    Time frame: Baseline over time until Week 72

  5. Pharmacokinetic parameters of VHB937 in serum - Cmax

    Cmax - The maximum concentration of VHB937 in serum

    Time frame: Baseline over time until Week 72

  6. Pharmacokinetic parameters of VHB937 in serum - Tmax

    Tmax - The time to reach the maximum concentration of VHB937 in serum

    Time frame: Baseline over time until Week 72

  7. Pharmacokinetic parameters of VHB937 in serum - Ctrough

    Ctrough - Minimum observed concentration of VHB937 in CSF

    Time frame: Baseline over time until Week 72

  8. VHB937 immunogenicity in serum

    Determination of anti-VHB937 antibodies in serum at selected timepoints

    Time frame: Baseline over time until Week 72

07

Study locations

73 sites
  • Banner Alzheimers Institute
    Phoenix, Arizona 85006, United States
  • Irvine Center for Clinical Research
    Irvine, California 92618, United States
  • University of California San Diego
    La Jolla, California 92037, United States
  • University of California at Los Angeles
    Los Angeles, California 90095, United States
  • Jem Research Institute
    Atlantis, Florida 33462-6608, United States
  • Visionary Investigators Network
    Aventura, Florida 33180, United States
  • K2 Medical Research LLC
    Maitland, Florida 32751, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Charter Research The Villages
    The Villages, Florida 32162, United States
  • Alzheimers Research Treatment Ctr
    Wellington, Florida 33414, United States
  • Conquest Research
    Winter Park, Florida 32789, United States
  • Hawaii Pacific Neuroscience LLC
    Honolulu, Hawaii 96817, United States
  • University of Kansas Hospital
    Fairway, Kansas 66205, United States
  • ActivMed Practices and Research
    Methuen, Massachusetts 01844, United States
  • Citizens Memorial Hospital Neurology CLinic
    Bolivar, Missouri 65613, United States
  • Lou Ruvo Center for Brain Health
    Las Vegas, Nevada 89106, United States
  • UNC Hosp Invest Drug Serv Pharm
    Chapel Hill, North Carolina 27514, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • Neural Net Research
    Portland, Oregon 97225, United States
  • Abington Neurological Associates Ltd
    Willow Grove, Pennsylvania 19090, United States
  • University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229-3900, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • Novartis Investigative Site
    Camperdown, New South Wales 2050, Australia
  • Novartis Investigative Site
    Kogarah, New South Wales 2217, Australia
  • Novartis Investigative Site
    Box Hill, Victoria 3128, Australia
  • Novartis Investigative Site
    Heidelberg, Victoria 3084, Australia
  • Novartis Investigative Site
    Nedlands, Western Australia 6009, Australia
  • Novartis Investigative Site
    London, Ontario N6G 3H7, Canada
  • Novartis Investigative Site
    North York, Ontario M6A 2C8, Canada
  • Novartis Investigative Site
    Ottawa, Ontario K1N 5C8, Canada
  • Novartis Investigative Site
    Toronto, Ontario M3B 2S7, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5T 2S8, Canada
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310002, China
  • Novartis Investigative Site
    Shanghai, 200040, China
  • Novartis Investigative Site
    Brno, 602 00, Czechia
  • Novartis Investigative Site
    Prague, 160 00, Czechia
  • Novartis Investigative Site
    Toulouse, Haute Garonne 31059, France
  • Novartis Investigative Site
    Paris, 75013, France
  • Novartis Investigative Site
    Berlin, State of Berlin 12200, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    München, 80377, Germany
  • Novartis Investigative Site
    Milan, MI 20132, Italy
  • Novartis Investigative Site
    Cefalù, PA 90015, Italy
  • Novartis Investigative Site
    Perugia, PG 06129, Italy
  • Novartis Investigative Site
    Ōbu, Aichi-ken 4748511, Japan
  • Novartis Investigative Site
    Fujioka, Gunma 3750017, Japan
  • Novartis Investigative Site
    Kodaira, Tokyo 1878551, Japan
  • Novartis Investigative Site
    Shinjuku Ku, Tokyo 1600023, Japan
  • Novartis Investigative Site
    tabashi City, Tokyo 1730015, Japan
  • Novartis Investigative Site
    Amsterdam, 1081 GN, Netherlands
  • Novartis Investigative Site
    Bialystok, 15-756, Poland
  • Novartis Investigative Site
    Oświęcim, 32-600, Poland
  • Novartis Investigative Site
    Wroclaw, 53-659, Poland
  • Novartis Investigative Site
    Seoul, Korea 05505, South Korea
  • Novartis Investigative Site
    Seoul, Seoul 03080, South Korea
  • Novartis Investigative Site
    Seoul, Seoul 05030, South Korea
  • Novartis Investigative Site
    Incheon, 21565, South Korea
  • Novartis Investigative Site
    Incheon, 22332, South Korea
  • Novartis Investigative Site
    Seoul, 04763, South Korea
  • Novartis Investigative Site
    Pamplona, Navarre 31008, Spain
  • Novartis Investigative Site
    Valencia, Valencia 46017, Spain
  • Novartis Investigative Site
    Valencia, 46026, Spain
  • Novartis Investigative Site
    Mölndal, 431 80, Sweden
  • Novartis Investigative Site
    Stockholm, 141 86, Sweden
  • Novartis Investigative Site
    Edinburgh, Lothian EH12 5PJ, United Kingdom
  • Novartis Investigative Site
    Oxford, Oxfordshire OX3 7JX, United Kingdom
  • Novartis Investigative Site
    Aberdeen, AB25 2ZH, United Kingdom
  • Novartis Investigative Site
    London, SE5 8AF, United Kingdom
  • Novartis Investigative Site
    London, W1G 9JF, United Kingdom
  • Novartis Investigative Site
    London, WC1N 3BG, United Kingdom
  • Novartis Investigative Site
    Newcastle upon Tyne, NE4 6BE, United Kingdom
  • Novartis Investigative Site
    Salford, M6 8HD, United Kingdom
  • Novartis Investigative Site
    Southampton, SO16 6YD, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Sep 2028, 37 months after the start.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 37 months is above that.

Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2025
First posted
Jul 30, 2025
StartActual
Aug 7, 2025
Primary completionEst.
Sep 14, 2028
CompletionEst.
Dec 31, 2030
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 21, 2026
Sites
2 sites added, 3 sites removed
Show 2 added (1 Italy, 1 Japan)
  • Novartis Investigative Site · Milan, Italy
  • Novartis Investigative Site · tabashi City, Japan
Show 3 removed
  • K2 Medical Research LLC · Maitland, United States
  • Alzheimers Research Treatment Ctr · Wellington, United States
  • Novartis Investigative Site · Itabashi Ku, Japan
across 2 updates, Oct 21, 2026 – Nov 5, 2026
Enrollment
407 (estimated)→96
Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    1 site added, 1 site removed
    Show site
    • Novartis Investigative Site · tabashi City, Japan
    Show 1 removed
    • Novartis Investigative Site · Itabashi Ku, Japan
    Enrollment 97→96
  2. Oct 21, 2026
    Recruiting→Active, not recruiting
    1 site added, 2 sites removed
    Show site
    • Novartis Investigative Site · Milan, Italy
    Show 2 removed
    • K2 Medical Research LLC · Maitland, United States
    • Alzheimers Research Treatment Ctr · Wellington, United States
    Enrollment 407 (estimated)→97 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07094516
Responsible party
Sponsor
First posted
Jul 30, 2025
Start date
Aug 7, 2025
Primary completion
Sep 14, 2028 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Nov 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion